495
Participants
Start Date
June 12, 2017
Primary Completion Date
February 3, 2021
Study Completion Date
February 3, 2023
Melflufen
Intravenous infusion
Pomalidomide
Oral capsules
Dexamethasone
Oral tablets
US06, Philadelphia
US-30, Winston-Salem
US-21, Salisbury
US11, Gainesville
US12, Orange City
US-19, Plantation
US-27, Hattiesburg
US-24, Louisville
US-18, Temple
US15, Fort Sam Houston
US16, Boise
US17, Tucson
US01, Fresno
US13, Boston
AT-02, Linz
AT-01, Vienna
BE-05, Edegem
BE-03, Liège
BE-02, Roeselare
CZ-05, Brno
CZ-03, Hradec Králové
CZ-04, Olomouc
CZ-01, Ostrava
Cz-02, Cz-06, Prague
DK01, Vejle
EE-01, Tallinn
EE-02, Tartu
FR04, Brest
FR-11, Cholet
FR01, Le Mans
FR05, Limoges
FR-07, Lyon
FR06, Lyon
FR03, Mulhouse
FR-09, Nice
FR-10, Périgueux
FR-08, Poitiers
Gr02, Gr03, Athens
GR04, Pátrai
GR01, Thessaloniki
Hu02, Hu03, Hu04, Budapest
HU01, Debrecen
HU-06, Kaposvár
HU-05, Pécs
IL03, Jerusalem
IL01, Nahariya
IL05, Rehovot
IL02, Safed
IL04, Tel Aviv
IL06, Tel Aviv
IT07, Bergamo
IT02, Bologna
IT08, Brescia
It03, It09, Milan
IT06, Modena
IT04, Piacenza
IT05, Terni
IT01, Torino
LT-02, Kaunas
LT-01, Vilnius
NL01, Rotterdam
NO-02, Ålesund
NO01, Oslo
PL03, Bialystok
PL02, Chorzów
PL06, Lodz
PL05, Lublin
PL-08, Olsztyn
PL07, Poznan
PL04, Rzeszów
PL-09, Torun
RO-02, Brasov
RO-01, Bucharest
RU-04, Izhevsk
Ru-11, Ru-14, Krasnoyarsk
RU-03, Moscow
RU-09, Nizhny Novgorod
RU-10, Novosibirsk
RU-06, Petrozavodsk
Ru-01, Ru-02, Ru-08, Ru-12, Ru-14, Saint Petersburg
RU-07, Samara
RU-13, Syktyvkar
RU-05, Yekaterinburg
KR-06, Busan
KR-05, Daegu
KR-04, Hwasun
Kr-01, Kr-02, Kr-03, Seoul
ES11, Badalona
Es02, Es13, Es14, Barcelona
Es01, Es04, Es09, Madrid
ES-15, Málaga
Es07, Es12, Pamplona
ES10, Salamanca
ES03, Santa Cruz de Tenerife
ES08, Seville
Es05, Es06, Valencia
TW-02, Chiayi City
Tw-04, Tw-07, Kaohsiung City
TW-03, Taichung
TW-05, Tainan City
Tw-01, Tw-06, Taipei
GB03, Liverpool
GB01, Manchester
GB02, Milton Keynes
GB04, Southampton
Lead Sponsor
Oncopeptides AB
INDUSTRY